NEWS RELEASE

RaQualia to Initiate First-In-Human Study for A Novel 5-HT_4 Partial Agonist RQ-00000010

February 29, 2012 – RaQualia Pharma Inc. (RaQualia) announced today that it had received the Letter of "Notice of Acceptance" for a Clinical Trial Application (CTA) from the Medicines and Healthcare products Regulatory Agency (MHRA) for its 5-HT_4 partial agonist (RQ-00000010) on February 29, 2012. RaQualia plans to initiate a first clinical trial (Phase I) for RQ-00000010 in the United Kingdom at the end of March 2012.

RQ-00000010 is a highly-selective serotonin receptor subtype 5-HT_4 partial agonist that promotes motility of the gastrointestinal (GI) tract superior to existing medicines with the same mechanism of action. In the non-clinical assessment, RQ-00000010 exhibited potent pharmacological effects on GI motility and excellent safety profiles without cardiovascular side effects including QTc prolongation. RQ-00000010 has the potential to be a significant new therapeutic option for the treatment of functional dyspepsia (FD) and other diseases related to GI motility disorders, including chronic constipation.

In this First-In-Human (FIH) study with single and multiple dosing, RaQualia plans to evaluate the effects of RQ-00000010 on gastric emptying using 13C breath test as well as safety, tolerability and pharmacokinetic profiles in man.

RaQualia engages in the discovery, development and marketing of drug candidates at both pre-clinical and clinical stages for highly-unmet medical needs. RaQualia explores and generates new development compounds, proves the product concept at an early stage of development, and delivers new medicines by partnering with pharmaceutical companies and bioventures worldwide.

####